A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CISH inactivated tumour infiltrating lymphocyte cell therapy Intima Bioscience (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
Indications Brain metastases; Carcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Intima Bioscience

Most Recent Events

17 Jan 2025 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.
17 Jan 2025 Planned primary completion date changed from 1 Sep 2023 to 1 Jan 2026.
17 Jan 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight